Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Shareholder Meeting (February 2024)
19 slides from Novo Nordisk A/s Class B's shareholder meeting presentation, Feb 22, 2024
Slide 1: Annual General Meeting 2024
Novo Nordisk A/S – Novo Nordisk A/S – Novo Alle 1, 2880 Bagsværd, Denmark – CVR no. 24256790 Annual General Meeting 2024 Juan Pablo Villaseñor lives with obesity and cardiovascular disease. Until recently, Juan struggled with stigma and often blamed himself for not being able to lose weight. Today,
Slide 2: The Board of Directors invites the shareholders to the 2024 Annual General Meeting
Novo Nordisk Annual General Meeting 2024 2 The Board of Directors invites the shareholders to the 2024 Annual General Meeting The Annual General Meeting of Novo Nordisk A/S (Novo Nordisk or the 'Company') will be held on Thursday 21 March 2024 at 14.00 (CET). The meeting will be held as a partially
Slide 3: Participate or View; Contact; Agenda
Novo Nordisk Annual General Meeting 2024 3 Participate or View Contact Participate at the Annual General Meeting, in person or virtually: Request an admission card via the Investor Portal latest by Friday 15 March 2024 at 23:59 (CET). Grant proxy or vote by correspondence: Fill in the proxy form lat
Slide 4: Elaboration on the items on the agenda: Remuneration
Novo Nordisk Annual General Meeting 2024 4 Elaboration on the items on the agenda Item 5: Remuneration Item 5.1: Approval of the remuneration of the Board of Directors for 2024 The remuneration of the Board of Directors was most recently adjusted in 2023. As mentioned in the notice for the Annual Ge
Slide 5: Board travel allowance and remuneration review
Novo Nordisk Annual General Meeting 2024 5 In addition, the Board of Directors proposes that the travel allowance is maintained at the same level as in 2023: 1. For Board meetings and committee - related meetings held in the home country of the Board member with five hours or more air travel each me
Slide 6: Indemnification scheme exclusions
Novo Nordisk Annual General Meeting 2024 6 Excluded from coverage under the Scheme are losses, etc., derived from: (a) Any claims if and to the extent covered by insurance taken out by Novo Nordisk, including any applicable D&O Insurance, it being understood that the indemnification may also cover c
Slide 7: Remuneration Policy changes
Novo Nordisk Annual General Meeting 2024 7 • The multipliers for the Research & Development Committee have been increased from 0.50 to 0.75 times the annual base fee for the chair and from 0.25 to 0.50 times the annual base fee for other committee members in light of the strategic importance of the
Slide 8: Share capital reduction and authorisation to repurchase own shares
Novo Nordisk Annual General Meeting 2024 8 Adoption of the proposal implies the following amendment of Article 3.1 of the Articles of Association taking effect upon completion of the capital reduction: “3.1 The Company’s share capital amounts to DKK 446,500,000 divided into A share capital of DKK 10
Slide 9: Additional information
Novo Nordisk Annual General Meeting 2024 9 Additional information Majority requirements To adopt the proposals under items 5.2(c), 8.1 and 8.3 of the agenda, at least two thirds of the total number of votes in the Company shall be present at the Annual General Meeting, and not less than two thirds o
Slide 10: How to participate
Novo Nordisk Annual General Meeting 2024 10 How to participate – participation in person, virtual participation or viewing the webcast Novo Nordisk offers three different ways for the shareholders to participate in or view the Annual General Meeting: • Participation in person. This includes the poss
Slide 11: Information on novonordisk.com; Dividends
Novo Nordisk Annual General Meeting 2024 11 Information on novonordisk.com The following information is available on www.novonordisk.com/AGM until and including the date of the Annual General Meeting: • Notice to convene the Annual General Meeting, including the agenda and complete proposals and a d
Slide 12: Appendix: Candidates for the Board, competences and experience
Novo Nordisk Annual General Meeting 2024 12 Appendix Candidates for the Board of Directors Competences and experience to be represented on the Board (shareholder - elected Board members only) Global corporate leadership Healthcare & Finance & accounting pharma industry Human capital Medicine & scien
Slide 13: The individual candidates
Novo Nordisk Annual General Meeting 2024 13 The individual candidates Helge Lund Chair Norwegian. Born October 1962. Male. Member since 2017. 1 Term 2024. Chair of the Nomination Committee and the Chair Committee. Independent Positions and management duties: Chair of the board of directors and chair
Slide 14: The individual candidates (continued)
Novo Nordisk Annual General Meeting 2024 14 The individual candidates (continued) Laurence Debroux Member of the Board French. Born July 1969. Female. Member since 2019. Term 2024. Chair of the Audit Committee and member of the Remuneration Committee. Independent Positions and management duties : Me
Slide 15: The individual candidates (continued)
Novo Nordisk Annual General Meeting 2024 15 The individual candidates (continued) Sylvie Grégoire Member of the Board Canadian and American. Born November 1961. Female. Member since 2015. Term 2024. Member of the Audit Committee, the Research & Development Committee and the Nomination Committee. Ind
Slide 16: The individual candidates (continued)
Novo Nordisk Annual General Meeting 2024 16 The individual candidates (continued) Christina Law (full name: Choi Lai Christina Law) Member of the Board Chinese. Born January 1967. Female. Member since 2022. Term 2024. Member of the Audit Committee. Independent Positions and management duties: Group
Slide 17: Employee-elected Board members
Novo Nordisk Annual General Meeting 2024 17 Employee - elected Board members are elected for a four - year term by the employees in Novo Nordisk A/S in Denmark. The most recent election of employee - elected Board members was conducted in February 2022 and the employee - elected Board members took o
Slide 18: Employee-elected Board members (continued)
Novo Nordisk Annual General Meeting 2024 18 Thomas Rantzau Member of the Board (employee - elected board member) Danish. Born March 1972. Male. Member since 2018. Term 2026. Employee representative. Member of the Nomination Committee. Not independent Positions and management duties: Lead auditor, In
Slide 19: Novo Nordisk A/S contact and signatures
Novo Nordisk A/S – Novo Alle 1, 2880 Bagsværd, Denmark – CVR no. 24256790 +45 4444 8888 (switchboard), novonordisk.com SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto d